Jian L Campian
Mayo Clinic · Academic and Community Cancer Research United · Mayo Clinic in Rochester
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jian L Campian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07301268 · GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaMayo Clinic · recruiting · Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma · principal investigator
- Ph2NCT06160206 · Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent GlioblastomaAcademic and Community Cancer Research United · recruiting · Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma · principal investigator
- Ph2NCT05465954 · Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaMayo Clinic · active not recruiting · High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma · principal investigator
- Ph1NCT02659800 · Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade GliomasSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Lymphopenia, Malignant Glioma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastomaR01CA288862 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2025 to 2026 · $647,041 awarded in 2026Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT06160206
- Adult Brain Tumor Consortium (ABTC)UM1CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI STUART A GROSSMAN · fiscal years 2014 to 2020Named on NCT02659800
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 12:41 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.J Transl Med · 2018426 citationsRCR 14.6
- 417 citationsRCR 37.4
- Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier.PLoS One · 2016178 citationsRCR 6.7
- A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.J Neurooncol · 201996 citationsRCR 4.0
- A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.J Neurooncol · 201673 citationsRCR 2.5
- A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).Neuro Oncol · 202073 citationsRCR 3.3
- Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.J Neurooncol · 201846 citationsRCR 1.8
- Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.J Neurooncol · 201938 citationsRCR 1.7
- A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys · 202435 citationsRCR 4.3
- Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.JAMA Oncol · 202434 citationsRCR 3.6